NR1H4 and metabolic dysfunction-associated steatohepatitis: Tropifexor is another non-steroidal FXR agonist with promising results in preclinical studies in non-alcoholic steatohepatitis (NASH) and currently under investigation in phase II studies in NASH and PBC (NTC02516605) [103, 104].